180 related articles for article (PubMed ID: 24606705)
1. Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.
Da Silva DM; Movius CA; Raff AB; Brand HE; Skeate JG; Wong MK; Kast WM
Virology; 2014 Mar; 452-453():279-86. PubMed ID: 24606705
[TBL] [Abstract][Full Text] [Related]
2. Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.
Da Silva DM; Woodham AW; Skeate JG; Rijkee LK; Taylor JR; Brand HE; Muderspach LI; Roman LD; Yessaian AA; Pham HQ; Matsuo K; Lin YG; McKee GM; Salazar AM; Kast WM
Clin Immunol; 2015 Dec; 161(2):197-208. PubMed ID: 26360252
[TBL] [Abstract][Full Text] [Related]
3. Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.
Da Silva DM; Woodham AW; Naylor PH; Egan JE; Berinstein NL; Kast WM
J Interferon Cytokine Res; 2016 May; 36(5):291-301. PubMed ID: 26653678
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression.
Woodham AW; Raff AB; Raff LM; Da Silva DM; Yan L; Skeate JG; Wong MK; Lin YG; Kast WM
J Immunol; 2014 May; 192(10):4748-57. PubMed ID: 24719459
[TBL] [Abstract][Full Text] [Related]
5. Loss of epidermal Langerhans cells occurs in human papillomavirus alpha, gamma, and mu but not beta genus infections.
Leong CM; Doorbar J; Nindl I; Yoon HS; Hibma MH
J Invest Dermatol; 2010 Feb; 130(2):472-80. PubMed ID: 19759549
[TBL] [Abstract][Full Text] [Related]
6. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.
Fahey LM; Raff AB; Da Silva DM; Kast WM
J Immunol; 2009 Mar; 182(5):2919-28. PubMed ID: 19234187
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation.
Fausch SC; Fahey LM; Da Silva DM; Kast WM
J Immunol; 2005 Jun; 174(11):7172-8. PubMed ID: 15905561
[TBL] [Abstract][Full Text] [Related]
8. A major role for the minor capsid protein of human papillomavirus type 16 in immune escape.
Fahey LM; Raff AB; Da Silva DM; Kast WM
J Immunol; 2009 Nov; 183(10):6151-6. PubMed ID: 19864613
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C.
Da Silva DM; Woodham AW; Rijkee LK; Skeate JG; Taylor JR; Koopman ME; Brand HE; Wong MK; McKee GM; Salazar AM; Kast WM
Papillomavirus Res; 2015 Dec; 1():12-21. PubMed ID: 26665182
[TBL] [Abstract][Full Text] [Related]
10. Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes.
Palmroth J; Namujju P; Simen-Kapeu A; Kataja V; Surcel HM; Tuppurainen M; Yliskoski M; Syrjänen K; Lehtinen M
Scand J Infect Dis; 2010 May; 42(5):379-84. PubMed ID: 20121650
[TBL] [Abstract][Full Text] [Related]
11. High-risk human papillomavirus E6 inhibits monocyte differentiation to Langerhans cells.
Iijima N; Goodwin EC; Dimaio D; Iwasaki A
Virology; 2013 Sep; 444(1-2):257-62. PubMed ID: 23871219
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses.
Fausch SC; Da Silva DM; Rudolf MP; Kast WM
J Immunol; 2002 Sep; 169(6):3242-9. PubMed ID: 12218143
[TBL] [Abstract][Full Text] [Related]
13. Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3alpha production.
Guess JC; McCance DJ
J Virol; 2005 Dec; 79(23):14852-62. PubMed ID: 16282485
[TBL] [Abstract][Full Text] [Related]
14. Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells.
Fausch SC; Da Silva DM; Kast WM
Vaccine; 2005 Feb; 23(14):1720-9. PubMed ID: 15705478
[TBL] [Abstract][Full Text] [Related]
15. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response.
Amador-Molina A; Hernández-Valencia JF; Lamoyi E; Contreras-Paredes A; Lizano M
Viruses; 2013 Oct; 5(11):2624-42. PubMed ID: 24169630
[TBL] [Abstract][Full Text] [Related]
16. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
Kalnin K; Chivukula S; Tibbitts T; Yan Y; Stegalkina S; Shen L; Cieszynski J; Costa V; Sabharwal R; Anderson SF; Christensen N; Jagu S; Roden RBS; Kleanthous H
Vaccine; 2017 Sep; 35(37):4942-4951. PubMed ID: 28778613
[TBL] [Abstract][Full Text] [Related]
17. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.
Ahmed AI; Bissett SL; Beddows S
Infect Genet Evol; 2013 Aug; 18():151-9. PubMed ID: 23722024
[TBL] [Abstract][Full Text] [Related]
18. MIP3 alpha stimulates the migration of Langerhans cells in models of human papillomavirus (HPV)-associated (pre)neoplastic epithelium.
Herman L; Hubert P; Caberg JH; Evrard B; Kedzia W; Boniver J; Delvenne P
Cancer Immunol Immunother; 2007 Jul; 56(7):1087-96. PubMed ID: 17146629
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms used by human papillomaviruses to escape the host immune response.
Kanodia S; Fahey LM; Kast WM
Curr Cancer Drug Targets; 2007 Feb; 7(1):79-89. PubMed ID: 17305480
[TBL] [Abstract][Full Text] [Related]
20. An epithelial organoid model with Langerhans cells for assessing virus-host interactions.
Jackson R; Eade S; Zehbe I
Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1773):20180288. PubMed ID: 30955491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
